AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

在其病因中，叶酸受体 α 自身抗体（Folate receptor alpha autoantibodies，FRAA）和 SLC19A1 基因变异常被重点提及。本研究旨在分析 ASD 和 CFD 患者中 SLC19A1 基因的 rs1051266 变异，并确定其与临床和实验室指标的关系。研究纳入了 227 名 ASD 儿童，其中 156 名患有 CFD。

Phase 2 Trial - Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer Phase 1 Trial - Intraoperative Imaging of Pulmonary Nodules by OTL38 Phase 1 Trial - ...

In this study, luvelta demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer across all levels of Folate Receptor-α (FRα) expression of 25% or greater ...

and it was hoping to file for accelerated approval of the folate receptor α-targeting ADC in mid-2027. Just a few months later, luvelta has been "deprioritised" while Sutro looks for a partner to ...

The SGO Annual Meeting will take place from March 14-17, 2025 in Seattle, Washington. In this study, luvelta demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer ...